Mizuho Maintains Outperform on Upstream Bio, Lowers Price Target to $50
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Mizuho analyst Joseph Catanzaro maintains Upstream Bio (NASDAQ:UPB) with a Outperform and lowers the price target from $51 to $50.
Mizuho analyst Joseph Catanzaro maintains Upstream Bio (NASDAQ:UPB) with a Outperform and lowers the price target from $51 to $50.